Canada26/06/2023

ISTH 2023

Under the Spotlight Symposium

Share this page

icon
icon
icon
icon
icon

Final Results of the WIL-31 Study – A New Treatment Standard for von Willebrand Disease Patients with Severe Bleeding?

Monday, June 26, 2023
1:15pm - 2:30pm ET
Room: 511

Join Alok Srivastava, Nathan Connell, Robert F. Sidonio Jr, Kateryna Vilchevska, Ana Boban and Claudia Khayat for an interactive session to explore the clinical and treatment journey of three VWD patients, as they transition from on-demand treatment to prophylaxis treatment.

The symposium focuses on new data regarding the use of wilate® prophylaxis to improve the lives of people with VWD. Topics presented include the importance of prophylaxis, including current guidelines on the management of VWD and how to identify patients who may benefit from prophylactic treatment. We discuss key learnings from the WIL-31 VWD prophylaxis study and WIL-31 patient cases from across the globe.

The symposium is open to congress participants in Montréal, and will be live-streamed for participants attending virtually.

Symposium Programme

Agenda

Speaker

Welcome and introduction

Alok Srivastava, IN

Why is Prophylaxis Not an Important Component of Care in VWD Patients?

Nathan Connell, US

Key Learnings from the WIL-31 VWD Prophylaxis Study

Robert F. Sidonio Jr., US

PATIENT CASES FROM WIL-31 STUDY:

Teenage Boy from Ukraine, with Type 2A VWD

Kateryna Vilchevska, UA

Adult Female from Croatia, with Type 3 VWD

Ana Boban, HR

Teenage Brothers from Lebanon, Living with VWD Inhibitors

Claudia Khayat, LB

Q&A and Concluding remarks

Meet the Speakers

Chair: Alok Srivastava

IN

Nathan Connell

US

Robert Sidonio Jr.

US

Kateryna Vilchevska

UA

Ana Boban

HR

Claudia Khayat

LB

Join live on One Source

In case you cannot join us in person for the ISTH congress in Montréal, we invite you to watch our symposium live on One Source, Octapharma's online platform.

The event is for healthcare professional only.